Deals

Abogen Biosciences Strikes Licensing and Option Deal with Novartis for ABO2203 – Up to $7.2 Billion to Advance the First mRNA‑Encoded T‑Cell Engager in Autoimmune Disease

Abogen Biosciences Co., Ltd. ("Abogen"), a clinical‑stage biotechnology group pioneering RNA innovation, announced that it has entered into a licensing and option agreement with Novartis AG (NYSE: NVS) to advance…

October 2, 2026

Dizal Receives $600 Million Upfront Payment from AstraZeneca as Global Sunvozertinib License Takes Effect – Only Dual‑Approved Oral TKI for EGFR Exon20ins NSCLC

October 1, 2026

Henlius Forms Strategic Partnership with Zhejiang Cancer Hospital to Advance High‑Quality Oncology Care in China

October 1, 2026

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.

HKG: 0013 HKG: 2607

HutchMed to Divest 45% Stake in Shanghai Hutchison Pharmaceuticals for $608 Million

January 2, 2025

ADC / XDC BeiGene

BeiGene Secures Global Rights to Duality Biologics’ B7H4 Targeted ADC DB1312/BG-C9074

March 3, 2025

AI HKG: 2228

Xtalpi Inc. Partners with Amazon Web Services to Accelerate Life Sciences Innovation

December 31, 2024

AI HKG: 0700

We Doctor Holdings Limited Files for IPO on Hong Kong Stock Exchange